Floatz logo

RAMIFENTANYL

Bariatric Surgery

Siirt Training and Research HospitalSmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Bariatric Surgery cohort.

Asset / SponsorPhaseRating
PROPOFOL
Hospital dos Lusíadas
Phase 4BB
Dynastat
Hospital dos Lusíadas
N/AD
CIS-DIAMMINEDICHLOROPLATINUM II
University College Dublin
N/AD
Bms-907351
Universitaire Ziekenhuizen KU Leuven
D
Cefazolin
Hospital dos Lusíadas
N/AD

View all 21 →

Same molecule, other indications

RAMIFENTANYL is also rated in:

morbid obesityDormant
BBB
Indicative ·
73 / 100
View asset →
cardiovascular disorderDormant
BBB
Indicative ·
73 / 100
View asset →
Anesthesia, GeneralDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →